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Introduction
To identify the mechanisms underlying pluripotency, a 
number of studies have been carried out, and these have 
been recently summarized [1]. Th e ﬁ rst two studies that 
characterized the ‘stemness gene’ list [2,3] identiﬁ ed 
about 250 putative genes involved in mouse embryonic 
stem cell (mESC) pluripotency, and many other genes are 
being studied today [4-7]. While these experiments 
identiﬁ ed many genes involved in maintenance of pluri-
potency, such as Oct-4, Nanog and Sox-2, they also 
usually showed that human ESCs (hESCs) are quite 
diﬀ erent from each other [4,8-10]. A more comprehensive 
study showed that although closely related, the 59 ESC 
lines showed heterogeneity in gene expression [11]. 
Interestingly, variations in gene expression were found 
not only for genes correlated with the pluripotent state or 
diﬀ erentiation, but also for housekeeping genes [12]. 
Th erefore, interactions among many genes likely form an 
active network that allows the pluripotent state to be 
main tained [13]. In addition, due to this variation between 
lines, better models need to be established to unders tand 
the true underlying mechanisms of pluripotency.
While gene regulatory networks that enhance our 
knowledge of pluripotency will help our understanding 
of stem cell biology, there are additional implications. As 
described below, ESCs are derived from the inner cell 
mass of a blastocyst [14,15]. Th erefore, the ESCs are 
closely related to the inner cell mass, from which, via 
post-implantation development, the embryo and fetus 
form. Th us, diﬀ erentiation of ESCs recapitulates the 
earliest stages of human development, and understanding 
Abstract
The study of pluripotent stem cells has generated much interest in both biology and medicine. Understanding the 
fundamentals of biological decisions, including what permits a cell to maintain pluripotency, that is, its ability to 
self-renew and thereby remain immortal, or to diff erentiate into multiple types of cells, is of profound importance. For 
clinical applications, pluripotent cells, including both embryonic stem cells and adult stem cells, have been proposed 
for cell replacement therapy for a number of human diseases and disorders, including Alzheimer’s, Parkinson’s, spinal 
cord injury and diabetes. One challenge in their usage for such therapies is understanding the mechanisms that 
allow the maintenance of pluripotency and controlling the specifi c diff erentiation into required functional target 
cells. Because of regulatory restrictions and biological feasibilities, there are many crucial investigations that are just 
impossible to perform using pluripotent stem cells (PSCs) from humans (for example, direct comparisons among 
panels of inbred embryonic stem cells from prime embryos obtained from pedigreed and fertile donors; genomic 
analysis of parent versus progeny PSCs and their identical diff erentiated tissues; intraspecifi c chimera analyses for 
pluripotency testing; and so on). However, PSCs from nonhuman primates are being investigated to bridge these 
knowledge gaps between discoveries in mice and vital information necessary for appropriate clinical evaluations. 
In this review, we consider the mRNAs and novel genes with unique expression and imprinting patterns that were 
discovered using systems biology approaches with primate pluripotent stem and germ cells.
© 2010 BioMed Central Ltd
Systems biology discoveries using non-human 
primate pluripotent stem and germ cells: novel 
gene and genomic imprinting interactions as well 
as unique expression patterns
Ahmi Ben-Yehudah1,2, Charles A Easley IV1,2, Brian P Hermann1,2, Carlos Castro1,2, Calvin Simerly1,2, Kyle E Orwig1,2, 
Shoukhrat Mitalipov3 and Gerald Schatten1,2*
R E V I E W
*Correspondence: schattengp@upmc.edu
2Departments of Ob/Gyn and Reproductive Sciences, University of Pittsburgh 
School of Medicine, Pittsburgh, PA 15213, USA
Full list of author information is available at the end of the article
Ben-Yehudah et al. Stem Cell Research & Therapy 2010, 1:24 
http://stemcellres.com/content/1/3/24
© 2010 BioMed Central Ltd
the gene regulatory networks in these cells will enhance 
our knowledge of the regulation of the earliest stages of 
development.
Currently, we lack much information on speciﬁ c stages 
in development. As described, all tissues of the embryo 
arise from the same cells; however, they are diﬀ erent 
from each other, not only in their morphology and 
function, but also in their total DNA content. While 
somatic cells are diploid, gametes are only haploid. We 
have almost no knowledge on how these initial cells are 
selected and diﬀ erentiated.
Another area that would beneﬁ t from the delineation of 
pluripotent gene networks is the better understanding of 
reproductive mechanisms. While the sperm meets the 
egg to form the zygote, what gene expression in the egg 
allows the ﬁ rst stages of development to proceed? Since 
in vitro fertilization (IVF) and other assisted reproductive 
technologies are so commonly used, can better under-
standing of these ﬁ rst stages increase the eﬃ  ciency of 
these technologies?
However, while ESC lines contribute to a chimera - 
which is when cells injected into a new blastocyst contri-
bute to all tissues in the newborn - epiblast lines do not. 
We have no understanding of the mechanisms that 
underline the diﬀ erence between these two types of cells.
ESCs have been studied not only for cell replacement 
therapy or basic stem cell biology, but also as a tool for 
development of better and safer drugs. Since the ESC 
lines resemble, in many aspects, the developing fetus, 
they can be used as a ﬁ rst and quick tool for drug screen-
ing without exposing pregnant mothers and their babies 
to harmful drugs. Th erefore, better understanding of 
gene regulatory networks that control these cells or allow 
them to diﬀ erentiate under speciﬁ c signals will allow the 
development of new therapies. Th ese therapies will be 
based on the ﬁ nding of new targets and hence the 
development of treatments speciﬁ cally for those targets 
and the processes they control.
Certain cancers have been suggested to have a stem cell 
origin. Treatment today is usually directed to the 
amplifying cell rather than to the source of the cancer. 
Hence, understanding of the gene networks that have 
changed from those in stem cells and have led to cancer 
will allow the development of new treatments for the 
cancer, and as described before, the development of 
speciﬁ cally targeted molecules for these pathologies.
To summarize, understanding of the gene regulatory 
networks that enable a cell to maintain its pluripotent 
phenotype are of great interest today. Better understand-
ing of these networks will lead to better understanding of 
basic biology questions, the control of the speciﬁ c 
diﬀ erentiation of stem cells into target cells for cell 
replacement therapy, and the development of new drugs 
and treatments for cancer, among other diseases. Th is 
review summarizes our current knowledge of gene 
expres sion networks in non-human primates, which 
resem bles the human model and also has greater 
advantages.
Embryonic stem cells
ESCs are deﬁ ned as a population of cells capable of self-
renewing while maintaining their pluripotency. ESCs 
diﬀ erentiate and give rise to cells from all three germ 
layers: ectoderm, mesoderm and endoderm, including 
the pancreas [16]. Th ese cells are derived from the inner 
cell mass of mammalian blastocyst stage embryos [17,18]. 
While mESCs were cloned over three decades ago, we 
have only recently celebrated our ﬁ rst decade of hESC 
derivation. Hence, our knowledge on hESCs is more 
limited than that on mESCs. While the two types of ESC 
share many features, such as the expression of the pluri-
potent marker OCT-4, they also diﬀ er from each other, 
such as the dependency of mESCs on leukemia inhibitory 
factor (LIF) to maintain pluripotency. Presumably, 
therefore, pathways that contribute to both pluripotency 
as well as speciﬁ c diﬀ erentiation might diﬀ er between 
mESCs and hESCs. Th us, our knowledge on gene 
expression in mESCs as well as their utilization for 
therapy must be veriﬁ ed in hESCs.
Nuclear transfer
While ESCs can be diﬀ erentiated into beta cells, utilizing 
them in human therapy poses a problem since they do 
not identically match the patient. Human ESC lines today 
were derived from ‘leftover’ blastocysts from IVF clinics. 
Hence, they might cause an immune reaction when 
trans planted into human patients. One possibility to 
overcome this problem is the generation of genetically 
similar ESCs to the patient. Th is process would require 
the use of the patient’s genome. While routinely carried 
out in mice, this process has been found to be more 
diﬃ  cult in other species. Nuclear transfer (NT; also 
termed therapeutic cloning) requires the enucleation of a 
donor egg and the removal of the spindle DNA. Into this 
enucleated egg a single diﬀ erentiated cell, usually a 
ﬁ broblast, is placed. Th e two cells fuse together, resulting 
in a single cell carrying the correct number of chromo-
somes. Th is cell then begins its development and will 
cleave until a blastocyst is formed, which contains an 
inner cell mass from which ESCs can be derived (termed 
NT-ESCs). For this process to succeed, a large number of 
processes are carried out within the cell, including 
reprogramming of the genome to an undiﬀ erentiated 
state. It is this process that lowers the eﬃ  ciency of NT-
derived blastocysts. Much is unknown about the results 
of reprogramming, and many theories have been 
developed, which are summarized by Yang and colleagues 
[19].
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While the best known successful NT was Dolly the 
Sheep, derived by Sir Ian Wilmut [20], NT has been 
successful in many species, including dog, cat, mouse, 
cow, goat and others [21-23]. Recently, primate cells have 
been cloned, though with low eﬃ  ciency [24]. Th ese 
results support the contention that human cells could 
also be generated by NT, though very signiﬁ cant 
bioethical challenges remain. Th e reasons for the low 
eﬃ  ciency of primate cloning are not clear, and better 
methods for cloning are being investigated.
A recent study showed that it would be diﬃ  cult to 
carry out intraspecies cloning [25]. In this method, 
enucleated animal eggs would be used to house the 
diﬀ erentiated cells, thereby overcoming one of the major 
Figure 1: Ingenuity analysis identifi es novel gene networks involved in the maintenance of pluripotency. Genes over-expressed in non-
human primate embryonic stem cells compared to fi broblasts are depicted in red. Genes shaded in green are over-expressed in fi broblasts. 
Genes that were diff erentially expressed in both of two previous studies [1,117] could be identifi ed in this representative pathway. For this analysis 
we compared all genes with a known Entrez gene ID.
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hurdles of this process: the lack of suﬃ  cient numbers of 
donor eggs. However, the control experiments in this 
study were lacking. While the authors were able to 
demon strate that there was no development in the cloned 
intraspecies cells, they did not show their ability to clone 
human cells, raising questions about the eﬃ  ciency of 
cloning in this study [25].
ESCs and NT-ESCs have been proposed as possible 
treatments for diseases such as Parkinson’s, Alzheimer’s, 
juvenile diabetes and others. Speciﬁ cally, NT-ESCs as cell 
replacement therapy - that is, using NT to derive ESCs - 
have a great advantage when compared to fertilized 
ESCs. Patients could provide their own ﬁ broblasts for the 
derivation of NT-ESCs, and the resulting line would be 
patient-speciﬁ c. However, since this process uses donated 
eggs that contain mitochondrial DNA, these cells are not 
identical to the donor patient [26]. Th erefore, the newly 
derived ESCs are mostly genetically similar to the donor, 
and hence might be rejected when fully diﬀ eren tiated 
cells are transplanted. In contrast, many patients could 
not (for gender reasons) and/or should not (for ethical 
reasons) [26,27] donate eggs for the derivation of 
fertilized ESCs, and even then the newly derived cells 
would only be similar but not identical to the ﬁ broblast 
from which they were derived, while fertilized ESCs can 
be closely related to the donor only if the egg donor is the 
patient herself or a ﬁ rst degree relative.
NT-ESCs and fertilized ESCs have been shown to have 
many similar properties, including the ability to diﬀ eren-
tiate into cells from all three germ layers [28]. Since most 
diﬀ erentiation procedures used for NT-ESCs will follow 
the same methods from fertilized ESCs, much emphasis 
is placed on generat ing NT-ESCs more eﬃ  ciently, and 
other studies are carried out to improve the diﬀ eren-
tiation procedures. As proof of principle, a number of 
publications have shown that NT-ESCs can be used for 
therapy. Th is was achieved in a Parkinson’s model [29] as 
well as a diabetic model in which NT-ESCs were 
diﬀ erentiated into beta cells [30], thereby bridging the 
gap between the two routes of research. Th e method of 
diﬀ er entiation for these NT-ESCs was based on protocols 
described previously [30]. Th ese cells were able to main-
tain normal glucose levels after transplantion into a diabetic 
mouse [30]; however, an increase in blood glucose levels 
was seen 8 weeks after transplantation, presumably 
because the cells were not fully diﬀ erentiated beta cells.
Induced pluripotent stem cells
One major goal of stem cell research is the generation of 
patient-speciﬁ c stem cells. While successful in mice [31], 
the derivation of genetically matched, patient-speciﬁ c 
human ESCs using somatic cell NT (SCNT) has not yet 
been accomplished. Furthermore, the use of donor oocytes 
or pre-implantation embryos to derive patient-speciﬁ c 
stem cells using techniques such as SCNT, cell fusion and 
parthenogenesis elicits ethical concerns. Th e recent 
advance in reprogramming adult somatic cells into ES-
like cells, termed induced pluripotent stem (iPS) cells, 
provides another avenue for generating patient-speciﬁ c 
stem cells without the ethical concerns of other 
methodologies. Th us, iPS cell derivation is the latest 
innovation for generating large pools of patient-speciﬁ c 
stem cells that can be used to treat a wide range of human 
diseases.
In 2006, Takahashi and Yamanaka [32] demonstrated 
that mouse embryonic ﬁ broblasts and adult tip ﬁ bro-
blasts could be reprogrammed into a pluripotent, ES-like 
state by transducing these cells with four transcription 
factors (Oct4, Sox2, Klf4 and c-Myc) along with a knock-
in Fbx15 neomycin-resistant reporter gene. After 2 weeks 
of culture, these mouse iPS cells exhibited similar 
characteristics to ESCs, such as alkaline phosphatase 
activity, expression of SSEA-1 and Nanog (two pluri-
potency markers), and the ability to diﬀ erentiate into all 
three germ layers (endoderm, ectoderm and mesoderm) 
via in vitro diﬀ erentiation or teratoma formation in 
immuno deﬁ cient mice. While this ground-breaking 
research provided a proof-of-principle for the repro-
gram ming of adult somatic cells to ES-like cells, these iPS 
cells diﬀ ered from ESCs in the genomic expression of 
several genes and the inability of the iPS cells to fully 
chimerize with donor mouse embryos. Shortly after the 
publication of this work, three groups showed that 
dispens ing with the reactivation of the Fbx15 reporter 
gene generated iPS cells that yielded fully chimerized 
pups following blastocyst injection and could contribute 
to germ cell transmission [33-35].
Recently, this work has been extended to human cells, 
as three groups originally demonstrated that human iPS 
cells could be generated from embryonic, neonatal and 
adult ﬁ broblasts [36-38]. Like ESCs, these human iPS 
cells exhibited alkaline phosphatase activity, expressed 
SSEA-3, TRA-1-60, Oct4 and Nanog (human pluri-
potency markers) from endogenous loci, and exhibited a 
genomic proﬁ le more similar to ESCs than the originating 
ﬁ broblasts. Interestingly, two diﬀ erent combinations of 
retrovirally introduced transcription factors were used: 
Oct4, Sox2, Klf4 and c-Myc were utilized by two groups 
[36,37], while Yu and colleagues [38] generated human 
iPS cells using Oct4, Sox2, Nanog and Lin28, an RNA 
binding protein that regulates synthesis of the let-7 family 
of microRNAs (miRNAs). Currently, this work has been 
repeated in several other labs and has included repro-
gramming of more terminally diﬀ erentiated cells, such as 
pancreatic beta cells [39-42].
Th e potential for iPS cells to be utilized therapeutically 
has recently been examined [43]. In this study, 
researchers were able to ameliorate a mouse sickle-cell 
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anemia model by diﬀ erentiating iPS cells into hemato-
poietic stem cells and re-introducing these cells back into 
the animal model [43]. Similarly, human iPS cells have 
been directly diﬀ erentiated into motor neurons and 
insulin-secreting islet-like clusters in vitro [44,45]. While 
these results highlight the great promise for iPS cells in a 
clinical setting, transplanting iPS cells or diﬀ erentiated 
iPS cells into humans carries a high risk. Around 20% of 
chimeric mice generated from iPS cells developed tumors 
within a 2- to 10-month time frame [34]. Th is ﬁ nding is 
most likely due to the reactivation of c-Myc in iPS cells. 
While dispensing with c-Myc in iPS cell formation 
reduces the overall eﬃ  ciency of obtaining iPS cell 
colonies, chimeric mice derived from these cells appear 
to be free of tumors [46,47]. However, aberrant expres-
sion of Oct4, Sox2, Klf4 and/or Nanog has been observed 
in a number of human malignancies [48-50]. Likewise, 
the random integration of the retroviruses could induce 
tumorigenesis by activating other oncogenic factors [51]. 
Because of these concerns, current research has been 
targeted at deriving iPS cells in a more clinically-friendly 
manner. Such protocols include using adenoviruses 
instead of retroviruses, and using miRNAs or a combi-
nation of chemical and genetic modiﬁ cations to induce 
reprogramming [52-54]. While iPS cell derivation is years 
away from being utilized in a clinical setting, the proof-
of-principal results shown thus far indicate that iPS cells 
have the promise of treating a wide range of human 
disorders without the concern of immuno-rejection. 
Also, without requiring donor oocytes or pre-implan ta-
tion embryos, iPS cell technology reduces the ethical 
concerns about generating patient-speciﬁ c, pluripotent 
stem cells (PSCs).
Germ cells
Another potential source of stem cells is derived from 
precursor germ cells. In early embryonic development, a 
subset of pluripotent cells diﬀ erentiate into primordial 
germ cells (PGCs) [55,56]. Th ese cells migrate, proliferate 
and colonize the genital ridge and represent a population 
of cells that will eventually further diﬀ erentiate to form 
gametes. Initially discovered in mice, failure of PGCs to 
mitotically arrest following colonization leads to the 
formation of teratomas, tumors that contain cells repre-
senting all three germ layers: ectoderm, mesoderm, and 
endoderm [57]. Th e ﬁ rst isolations and cultures of these 
proliferating PGCs yielded a multipotent cell line termed 
embryonal carcinoma cells. Th ese cells are capable of 
being diﬀ erentiated in culture into various cell types, 
including neurons and cardiomyocytes [58,59]. It was 
also shown that culture of isolated PGCs prior to genital 
ridge colonization resulted in germ cell colonies that 
express numerous pluripotency markers akin to those of 
ESCs, such as OCT-4 [60,61]. Th ese unique cells, termed 
embryonic germ cells (EGCs) were shown to be highly 
pluripotent. EGCs have previously been an interesting 
cell source for studying gametogenesis in vitro because 
mouse EGCs appear to follow similar diﬀ erentiation 
patterns as observed in in vivo gametogenesis [62]. 
However, ethical concerns about obtaining human EGCs 
have tamed interest in this ﬁ eld.
Several groups have shown the ability of mouse, non-
human primate and human ESCs to diﬀ erentiate into 
germ cell lineages, speciﬁ cally in vitro-derived PGCs 
(invPGCs) [63-79]. However, three groups in particular 
have demonstrated three diﬀ erent methodologies for 
faithfully deriving invPGCs from ESCs at higher eﬃ  ci-
encies [63-65]. Yamauchi and colleagues [64] successfully 
diﬀ erentiated cynomolgus monkey ESCs into germ cells 
by forming embryoid bodies (EBs) with retinoic acid and 
culturing these EBs for 28 days. At day 28, germ cells 
could be identiﬁ ed by positive immunostaining for 
SSEA1, VASA or DAZL. Furthermore, these researchers 
showed up-regulation of germ cell gene expression for 
CXCR4, NANOS1, NANOS2, NANOS3, VASA, PIWIL1 
and TEKT1 upon EB formation with retinoic acid for 
28  days. Likewise, this group was able to demonstrate 
that day 28 EBs grown in retinoic acid or bone 
morphogenetic protein (BMP)-4 elevated expression of 
the meiotic marker SCP1 but not SCP3. Kee and 
colleagues [63] showed that adherent diﬀ erentiation with 
a BMP cocktail (BMP4, BMP7 and BMP8b) induced 
diﬀ eren tiation of hESCs into invPGCs in 7 to 14 days. 
Using a green ﬂ uorescent protein (GFP) transgene driven 
by the VASA promoter, these researchers showed that 
diﬀ eren tiation medium supplemented with BMPs 
resulted in increased expres sion of two PGC markers in 
diﬀ eren tiating hESCs: VASA and DAZL. Kee and 
colleagues also demonstrated that VASA-GFP+ cells 
could be isolated and cultured on mouse embryonic 
ﬁ broblasts for 7 days to form invPGC colonies. Th ese 
cultured cells also exhibited hypomethylation of the H19 
locus, suggesting that these cells, like in vivo PGCs, 
undergo de-methy lation prior to gametogenic progres-
sion [63]. More importantly, Kee and colleagues demon-
strated that over expression of DAZ family members 
(DAZ, DAZL and BOULE) in cultured invPGCs induces 
meiotic progres sion as determined by immunoﬂ uor-
escence staining for SCP3 and γH2AX [63]. Even more 
striking, they demonstrated haploid formation by over-
expression of the DAZL family members by the appear-
ance of a small 1N peak in their propidium iodide FACS 
analysis and the expression of acrosin in a small fraction 
of cells. Th is remarkable discovery highlights the poten-
tial of driving gametogenesis in vitro from PSCs [63].
More recently, Amander Clark’s group demonstrated a 
novel approach for rapidly and more eﬃ  ciently diﬀ eren-
tiating hESCs into PGCs. Park and colleagues [65] 
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showed that diﬀ erentiation of hESCs on human fetal 
gonadal stromal cells signiﬁ cantly improved germ cell 
diﬀ erentiation. Strikingly, these researchers showed that 
c-kit+/SSEA1+/VASA+ invPGCs (5% of the total popu la-
tion of cells) could be isolated from diﬀ erentiated hESCs 
as early as 3 days of culture on human fetal gonadal 
stromal cells. Similarly to Kee and colleagues, Park and 
colleagues demonstrated that invPGCs exhibit imprint 
erasures and show expression of a wide range of germ cell 
markers [63,65]. Th e work of Park and colleagues demon-
strates progress towards a highly eﬃ  cient methodology 
for generating PGCs from ESCs in vitro [65]. Further-
more, Park and colleagues are the ﬁ rst group to 
diﬀ erentiate human iPS cells into early germ cell lineages. 
Th ese exciting results combined with the work of Kee 
and colleagues [63] and Yamauchi and colleagues [64] 
high light the similarities between in vivo PGCs and 
invPGCs illustrate the possibility of treating infertility by 
diﬀ erentiating patient-matched ESCs into gametes or 
male germline stem cells for transplantation.
Th e ability to generate transplantable male germline 
stem cells or haploid gametes in culture has signiﬁ cant 
therapeutic implications for couples with infertility 
[80,81]. Th e appeal of these approaches is enhanced by 
iPS cell and NT technologies, which would theoretically 
enable men to derive germline stem cells or sperm from 
their own skin cells in vitro. Th us, it is hypothetically 
possible for a man who is rendered infertile by toxic 
treatment for cancer (chemotherapy or radiation), and 
who did not cryopreserve semen prior to treatment, to 
father his own genetic children from germ cells derived 
from NT-ESCs or iPS cells. Th is potential can only be 
realized after extensive feasibility and safety studies are 
conducted, ideally in nonhuman primate models that are 
relevant to human physiology. Th ere is a lack of consen-
sus among species regarding the potential of PGCs to 
undergo spermatogenesis when introduced into semini-
ferous tubules (mouse PGCs can [82] and rat PGCs cannot 
(K Orwig, unpublished)). However, there is con sen sus in 
rodents and several large animal species that gono cytes 
and spermatogonia from neonate, pup and adult testes 
undergo spermatogenesis when trans planted into the 
testes of infertile recipients [82-87].  Human PSCs can be 
diﬀ erentiated into PGCs in the context of EBs [70,88] or 
adherent diﬀ erentiation cultures [63,65,67]. Similarly, two 
groups have reported macaque PSC to PGC diﬀ eren tiation 
in EBs [64,89]. Th ere are no reports of PSC to spermato-
gonial stem cell (SSC) diﬀ erentiation, but several studies 
have reported PSC diﬀ erentiation to haploid germ cells 
[63,77,78], suggesting a transient transition through an 
SSC-like intermediate. Th us, direct diﬀ erentiation of PSCs 
to SSCs would provide a source of transplantable cells that 
could be used to ask important questions about the safety 
and eﬃ  cacy of PSC-derived cells.
Interestingly, the postnatal mammalian testis itself may 
provide an alternative source of PSCs that bypasses the 
need for an embryonic intermediate or genetic manipu-
lation. Several groups have shown the ability of germ cells 
in the mouse postnatal testis to produce PSCs in vitro 
[90-96]. Several recent studies have also provided 
evidence for PSCs derived from the adult human testis 
[97-100]. Th ese cells arise in vitro from spermatogonia 
and can give rise to tissues of all three embryonic germ 
layers. Given that germ cells are responsible for initiating 
embryogenesis, it seems possible that germ cell factors 
could inﬂ uence their ability to become pluripotent (for 
example, including expression of genes associated with 
pluripotency). Among the genes that are thought to form 
a core regulatory network in ESCs (OCT4, SOX2, and 
NANOG) [101], only OCT-4 is expressed by a few 
postnatal germ cells or cultured SSCs. Several reports 
have described a relatively small group of normal mouse 
spermatogonia that express OCT-4, including those in 
the adult testis, which could potentially be those that 
have the capacity to produce PSCs in vitro [102-107]. In 
human spermatogonia, though, only a few postnatal 
spermatogonia retain embryonic-expressed OCT-4, and 
this expression is lost after the ﬁ rst few months of infant 
life except in pathological conditions [108,109]. In 
cultured SSCs, Oct-4 mRNA and protein can be detected, 
albeit at substantially lower levels than in ESCs 
[90,95,110,111], and this feature may be required for 
long-term survival of SSCs in culture [112]. Th us, the 
mechanisms that predispose spermatogonia (presumably 
SSCs) to acquire a pluripotent phenotype in a culture 
dish are unclear, but may involve similar gene expression 
features with other pluripotent cells (ESCs).
Gene expression in non-human primate ESCs
Th ere are great challenges working with human ESC lines 
rather than ESC lines from pedigreed animals. While 
working with human ESC lines involves some ethical as 
well as religious issues, use of non-human primate ESC 
(nhpESC) lines alleviates many of these concerns. Our 
two groups have recently derived a large number of 
nhpESC lines, including from rhesus macaques and 
baboon, using both fertilized blastocysts and NT 
[9,113-118]. In addition, others have derived other 
monkey ESC lines, such as from marmoset [119]. Th ere 
are many other advantages in working with nhpESC 
compared to hESC lines: namely, the use of prime quality 
embryos as compared to left over human IVF embryos 
donated to science that usually either have genetic 
disorders [120] or lag in their development. In addition, 
since the donors of primate gametes are not anonymous, 
we have much information on the parents, as opposed to 
the anonymity of human donors. For these reasons we 
have closely examined the factors that deﬁ ne a stem cell 
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line, including genes expressed, and compared them to 
the literature on gene and mRNA expression of human 
ESCs.
Using the newly derived nhpESC lines, we examined 
their gene expression [9] and found that they are very 
similar (>97%) to each other. We next compared the gene 
expression of these lines to that of two types of ﬁ broblast: 
skin ﬁ broblasts from the parents from which gametes 
were taken to derive the lines; and ﬁ broblasts derived 
from teratomas generated by the injection of nhpESCs 
into severe combined immunodeﬁ ciency (SCID) mice 
[1]. We found a unique set of genes that is diﬀ erentially 
expressed between the nhpESCs and the two types of 
ﬁ broblast. Interestingly, many of these genes were 
membrane-bound proteins and receptors [1] (Table  1). 
We have also shown that there are chromosomes that 
show an overabundance of over-expressed genes, such as 
chromosomes 16, 19 and X, which correlate to human 
chromosomes 17, 20 and X, respectively.
Our second study [114] has shown that there is indeed 
a unique set of genes in nhpESCs that maintains 
pluripotency, and that these diﬀ erentially expressed 
genes are involved in many pathways. As expected, both 
studies revealed the over-expression of the ‘classic’ stem 
cell factors OCT-4, Nanog and Sox-2 (Table 1). Interest-
ingly, when imprinting was examined, the nhpESCs were 
found to have aberrant imprinting, the implications of 
which are unknown [121].
When the two studies are compared, as depicted in 
Table 1, many of the top diﬀ erentially expressed genes are 
similar. Taking into account that these were two separate 
studies, the resemblance between the two gene lists is 
striking. While Ben-Yehudah and colleagues [1] com-
pared the gene expression of nhpESCs to ﬁ broblasts and 
generated a list of genes over-expressed in ESCs, 
Mitalipov and colleagues [117] generated a list of genes 
that were highly expressed in a number of nhpESC lines. 
Out of the top 25 genes over-expressed in nhpESCs in 
both studies, 6 (24%) were found on both lists. As 
expected, genes known to be involved in maintenance, 
such as OCT-4 and Nanog, can be found on both lists. 
Additionally, PTPRZ1 is found on both lists; this gene has 
been shown to be expressed by hESCs and is down-
regulated upon diﬀ erentiation. Depletion of PTPRZ1 
resulted in decreased colony formation and lower 
recovery of hESCs. However, the lists include genes that 
have yet to be associated with pluripotency, such as 
TACSTD1. TACSTD1, also called Ep-CAM, is an epi-
thelial adhesion molecule that was originally identiﬁ ed as 
a marker of carcinomas and is also expressed by rat SSCs 
[122-124]. We found this gene to be the most 
diﬀ erentially expressed gene between stem cells and 
ﬁ broblasts, indicating that it might have other functions 
in signaling rather than solely adhesion. In addition, it 
should be pointed out that 40% of the genes on the list in 
Ben-Yehudah and colleagues [1] are hypo thetical; these 
genes may also play a signiﬁ cant role in pluripotency.
When we compiled the data in Ben-Yehudah and 
colleagues [1] using Ingenuity software to identify system 
networks responsible for the regulation of the pluripotent 
state in nhpESCs, we were able to create many gene 
networks. Some of these networks contained anticipated 
candidate genes, including SOX2, OCT-4 and NANOG, as 
we have shown previously [1]. In addition we could 
identify networks that have been shown to be diﬀ eren tially 
expressed between stem cells and ﬁ broblasts, as depicted 
in Table 1. Th ese genes participate in networks that have 
yet to be associated with pluripotency. Although most of 
the genes depicted in Figure 1 and Table 1 are unidentiﬁ ed 
or have not been associated with pluripotency, some were 
found to play roles in regulating the transition from 
pluripotency to diﬀ erentiation; for example, the gene 
TACSTD1 is included in both Figure 1 and Table 1.
Since ESCs can serve as a method of studying 
development [125], much research has been carried out 
to understand the mechanisms that underlie regulation 
of this speciﬁ c process, such as the gene regulatory 
networks that control pluripotency. Th ese regulatory 
networks have been studied in mice [126] and have 
revealed the importance of key regulators of the pluri-
potent state, including OCT-4, Sox-2 and Nanog. A 
comprehensive review described similar ﬁ ndings in 
humans [127,128] and has also been discussed by us [1]. 
It should be pointed out that although many genes have 
been implicated in the networks controlling pluripotency, 
little is known about the networks controlling this 
process. An exception is the OCT-4/Sox-2/Nanog net-
work, which has been shown to be invaluable for main-
taining pluripotency. In our hands, we could identify the 
pluripotent genes and networks [1,24], but could not ﬁ t 
all the diﬀ erentially expressed genes into these networks 
or form new ones.
Imprinted genes in nhpESCs
While genes involved in pluripotency can be identiﬁ ed and 
even gene regulatory networks can be described, other 
mechanisms controlling the expression of genes in 
pluripotent cells can be established - for example, epi-
genetic mechanisms that control gene expression in pluri-
potent cells. One such epigenetic mechanism is DNA 
methylation, which is considered a key factor in the 
formation of cellular memory and identity [129]. A 
comprehensive review summarized the key features of the 
regulatory mechanisms that control the trans crip tional 
regulatory features in hESCs [130,131], which 
complemented their work with ChIP-chip in mESCs [132].
Th e rhesus monkey is the only primate in which SCNT 
has been successful so far [133]. Th erefore, this model 
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can help answer questions on the epigenetic state of cells 
that undergo reprogramming - for example, whether they 
are closer to ESCs or to the somatic cell from which they 
originate. Th e answer to this question might shed light on 
why it is very diﬃ  cult for primate cells to undergo NT 
compared to mice and other animals. Th is could lead to 
improvements in primate NT.
We have recently compared DNA methylation in native 
ESCs, ﬁ broblasts, and ESCs generated by SCNT [129]. 
We wished to examine if the SCNT cells undergo changes 
in methylation state that would resemble a stem cell 
rather than a somatic cell. We have identiﬁ ed and com-
pared epigenome programming and reprogramming. 
Based on our previous knowledge, we have characterized 
hundreds of regions that are hyper- or hypomethylated in 
ﬁ broblasts compared to native ESCs. We found that these 
regions are conserved in human cells and tissues. When 
ESCs were compared to the SCNT cells, we found to our 
surprise that the vast majority of these regions were 
reprogrammed in SCNT ESCs. Th e meaning of these 
phenomena is that these cells do indeed undergo repro-
gramming of their DNA methylation during SCNT. Th is 
reprogramming leads to an almost perfect corre lation 
between the epigenomic proﬁ les of the native (ESC) and 
reprogrammed (NTSC) lines.
We also found that at least 58% of these changes are 
correlated in cis to transcription changes, Polycomb 
repressive complex-2 occupancy, or binding by the CTCF 
insulator [129].
As expected, since the process of adding or removing 
a methyl group from the DNA must be a complex 
process, we found that while epigenomic repro gram-
ming is extensive and globally accurate, the eﬃ  ciency of 
adding and stripping DNA methylation during 
reprogramming is regionally variable. In several cases, 
this variability results in regions that remain methylated 
in a ﬁ broblast-like pattern even after reprogramming 
[129].
Table 1. Twenty-fi ve genes over-expressed in Ben-Yehudah and colleagues [1] and Mitalipov and colleagues [117] 
 Top 25 over-expressed genes in [1]   Top 25 over-expressed genes in [117]
 Aff ymetrix ProbeSet ID  Gene symbol  Aff ymetrix ProbeSet ID  Gene symbol
1 MmuSTS.2870.1.S1_at TACSTD1  MmuSTS.3741.1.S1_at PTPRZ1
2 MmugDNA.35532.1.S1_at LOC697750  MmugDNA.32128.1.S1_at NANOG
3 MmuSTS.4178.1.S1_at CTSL2  MmugDNA.33796.1.S1_s_at FLJ16517
4 MmugDNA.17159.1.S1_at NFE2L3  MmugDNA.12465.1.S1_at LIN28
5 MmugDNA.20158.1.S1_at NELL2  MmuSTS.1454.1.S1_at MAL2
6 MmugDNA.11043.1.S1_at LOC705355  MmuSTS.2862.1.S1_at SPP1
7 MmunewRS.431.1.S1_at NPY1R  MmuSTS.3364.1.S1_at PDZK1
8 MmuSTS.2285.1.S1_at POU5F1  MmugDNA.37987.1.S1_at SALL1
9 MmunewRS.475.1.S1_at LOC703107  MmuSTS.1929.1.S1_at MYCN
10 MmugDNA.24757.1.S1_at LOC702395  MmugDNA.20158.1.S1_at NELL2
11 MmuSTS.3573.1.S1_at PCDH8  MmuSTS.2870.1.S1_at TACSTD1
12 MmuSTS.3621.1.S1_at CHGB  MmugDNA.17017.1.S1_at OTX2
13 MmuSTS.4813.1.S1_at GABRB3  MmugDNA.24774.1.S1_s_at APOA1
14 MmugDNA.38382.1.S1_at LOC696162  MmuSTS.1037.1.S1_at SH3GL3
15 MmugDNA.41477.1.S1_at NLGN4X  MmugDNA.11977.1.S1_at MBD2
16 MmugDNA.17159.1.S1_s_at NFE2L3  MmugDNA.33242.1.S1_at PODXL
17 MmugDNA.19721.1.S1_at LOC696085  MmugDNA.6117.1.S1_at CECR2
18 MmuSTS.3827.1.S1_at LOC696132  MmuSTS.4090.1.S1_at EBAF
19 MmugDNA.32128.1.S1_at Nanog  MmugDNA.36148.1.S1_at CYP26A1
20 MmugDNA.27729.1.S1_at SOX2  MmuSTS.2285.1.S1_at POU5F1
21 MmuSTS.3741.1.S1_at PTPRZ1  MmugDNA.3748.1.S1_at LOC112868
22 MmugDNA.7641.1.S1_at LOC712710  MmugDNA.32848.1.S1_at ST8SIA4
23 MmugDNA.33796.1.S1_s_at LOC696130  MmuSTS.214.1.S1_at ZIC3
24 MmugDNA.26523.1.S1_s_at NFE2L3  MmuSTS.1436.1.S1_at LCK
25 MmugDNA.31842.1.S1_s_at LOC696002  MmuSTS.4824.1.S1_at GDF3
Underlined genes are those diff erentially expressed in both studies; genes in bold are as yet uncharacterized genes. 
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Small RNAs and other RNAs
We have carried out many systems analyses using 
Ingenuity, as described in Figure 1. Th ese usually identi-
ﬁ ed networks not directly associated with pluripotency. 
However, we could occasionally identify a connection 
between genes associated with pluripotency and unique 
genes. One example is depicted in Figure 2. While Sox2 
and Nanog are expressed in pluripotent cells (red), they 
are also associated with the gene NCRNA00094. Th is 
gene has been shown previously to be a non-coding 
RNA with unknown activity that is expressed in ESCs 
[134].
NCRNA00094 is an example of a large number of non-
coding RNAs that might play a role in maintaining 
pluripotency. One subtype of non-coding RNAs that has 
been shown to participate in this process is the miRNAs. 
miRNAs are short non-coding RNA sequences that 
control gene expression by inhibiting the translation of 
speciﬁ c mRNAs or causing their degradation [135,136]. 
Hence, several studies have been carried out to ﬁ nd 
miRNAs involved in the maintenance of pluripotency in 
ESCs. Using mathematical and statistical tools, a recent 
study [137] identiﬁ ed miRNAs that might be involved in 
pluripotency. A similar study was carried out in mESCs 
[138,139] and hESCs [140-142]. When diﬀ erent types of 
human adult and ESCs are compared, a number of 
miRNAs seem to be involved in this process, such as 
miR302 [53,136,142-144]. Speciﬁ cally, one study showed 
Figure 2. Non-coding RNAs can be identifi ed as members of pluripotent pathways using Ingenuity. Ingenuity analysis shows that genes 
known to be involved in stemness (Nanog and Sox-2) are over-expressed (red) in non-human primate embryonic stem cells (nhpESCs) compared 
to fi broblasts. In addition, we could identify non-coding RNAs that were over-expressed in nhpESCs and associated with Nanog. For this analysis we 
compared all genes with a known Entrez gene ID.
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a connection between the ‘stem cell factors’ and miRNAs 
that inhibit them [145]. However, more work has to be 
done to identify their speciﬁ c targets and actions, such as 
the crosstalk between stem cell factors and miRNAs, as 
in the case of Lin-28 and Let7, for example [139].
A comprehensive comparison of gene and RNA proﬁ les 
of mouse fertilized and SCNT lines has been carried out 
recently [146]. Th ey found that the two types of ESCs 
have similar miRNA and protein expression proﬁ les. 
Th ey conclude that this phenomenon is consistent with 
their similar developmental potentials and might result 
from their similar transcriptional proﬁ les.
While much research has been conducted on miRNA 
involvement in pluripotency in hESCs and mESCs, this 
has been little studied in the monkey. A recent study by 
some of us [137] has computationally searched the rhesus 
genome to identify novel miRNAs involved in pluri-
potency by homology to human miRNAs. Th is study 
identiﬁ ed 383 novel miRNAs: 173 have 100% homology 
to human miRNAs and 281 have >90% homology in the 
seed sequence of the miRNAs [137]. Th is study also 
identiﬁ ed miRNAs that are involved in human ESC 
pluripotency, such as miR302, as described above.
Conclusions
In this review we have summarized our and other results 
from the past decade on the generation of nhpESCs, 
SCNT, the generation of iPS cells and our work on 
primordial germ cells. All these ﬁ elds of research cumu-
latively enhance our understanding of the early stages of 
human development. Th ese exciting results, together 
with our results on gene expression in rhesus macaques 
and other primates, open the possibility of studying the 
gene expres sion and its control by miRNAs that results in 
the undiﬀ erentiated state of ESCs. Moreover, these studies 
may lead to better understanding of the mecha nisms 
behind processes such as induced pluripotency, the 
knowledge of which could be used to test cellular therapies 
in nonhuman primates before introduction in humans.
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